Our deeply established relationships in the pharmaceutical industry makes us the unrivalled advisor for your cross-border transaction
The Results Healthcare team is dedicated to advising large pharma corporates and smaller biotech businesses as well as companies which provide direct technical services to these companies, on bringing innovative drugs and treatments to market for the benefit of patients and society. Our extensive international relationships in the pharma and biotech industry sets us apart from our competitors and our focus on supporting our clients in their strategic initiatives to create new business models, drive external growth and increase profitability makes us the unrivalled advisor for the sector.
Contract research organisations (CROs) and contract manufacturing organisations (CMOs) are among the strongest growth sectors of the pharmaceutical industry, with many firms experiencing double-digit annual growth. We work with CROs and CMOs in organisation asset restructuring and building core divisions through M&A activity.
Our team has a strong track-record having advised on some of the most important deals in the space including INC Research on signing its definitive merger agreement with inVentiv, GHO Capital, on its acquisition of Sterling Pharma Solutions and Linguamatics on its acquisition by IQVIA.
A combination of our deep sector knowledge and long-standing industry relationships enables us to get the best outcomes for our clients.
The medical technology sector (medtech) has long benefited from rising demand from demographic factors and the rapid expansion of international markets. More recently, innovation has created the opportunity for step change growth, with the advent of ‘smart devices’ and the introduction of digital technology to the bedside and the operating theatre.
Results Healthcare, with our international capability and deep understanding of healthcare systems in multiple territories, is ideally positioned to support clients to make the most of the growth opportunities in the manufacture, supply and distribution of medical equipment and consumables.
10 Dec 2020
Cell and Gene Therapies: Challenges in Scale-up to Commercial Manufacturing
The cellular therapy and gene therapy fields are undergoing very rapid growth. This includes a large and growing number of…
19 Aug 2020
Rising to the challenge: the response of UK biopharmaceuticals to the COVID-19 pandemic
Hindsight is a gift that every politician desires and with it, perhaps we would have been better prepared for the…
05 Jan 2021
Results Healthcare advises Charterhouse on its investment in Phastar
Results Healthcare is pleased to announce that it has advised Charterhouse Capital Partners, one of the longest established private equity…
09 Jul 2020
Deal activity and valuations in the healthcare sector during COVID-19
There has been a measurable impact on healthcare deal activity and valuations as a result of COVID-19. Major equity indices…
15 Nov 2019
Private equity appetite for the life sciences sector
Private equity firms are finding more creative ways to increase their investment in the life sciences sector. The life sciences…
Subscribe to receive our latest sector-specific research on M&A activity and fundraisings: